Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Jaktinib on QT/QTc Interval in Healthy Participants
NCT06193148Phase 1Completed
- Sponsor
- Zelgen
- Start
- Mar 2024
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of jaktinib in myelofibrosis (MF) (4 arms), sponsored by Zelgen. Primary endpoint: QT Interval Corrected Using Fridericia's Formula at 48 hours. Started Mar 2024; status: completed.
02
Drugs
jaktinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT06193148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06193148.